소외열대질환(NTD) 치료 시장 : 약제 유형별, 질환별, 투여 경로별, 치료 접근별, 최종 사용자별, 유통 채널별 - 시장 예측(2026-2032년)

The Neglected Tropical Disease Treatment Market was valued at USD 6.83 billion in 2025 and is projected to grow to USD 7.29 billion in 2026, with a CAGR of 6.74%, reaching USD 10.79 billion by 2032.

A strategic framing of neglected tropical disease treatment priorities, delivery challenges, and the imperative for integrated public health interventions that drive sustained outcomes

Neglected tropical diseases remain a defining public health challenge in many low- and middle-income settings, demanding coordinated clinical, logistical, and policy responses. In recent years, the confluence of environmental change, population movements, and evolving health system capacities has reshaped how treatment interventions are prioritized and delivered. Consequently, stakeholders across public health agencies, non-governmental organizations, clinical providers, and pharmaceutical manufacturers must align their approaches to preserve treatment efficacy, extend reach, and sustain community trust.

This analysis introduces the current treatment landscape by situating core clinical interventions within broader delivery and regulatory contexts. It emphasizes the need for integrated strategies that bridge mass drug administration approaches with targeted therapies, while recognizing the role of primary care sites, community health networks, and mobile outreach in closing access gaps. To that end, the introduction sets the stage for subsequent chapters that examine systemic shifts, policy headwinds, segmentation-specific insights, and practical recommendations for leaders seeking to translate evidence into impact.

How scientific advances, shifting epidemiology, and evolving procurement models are redefining treatment paradigms and supply chain resilience for neglected tropical diseases

The treatment landscape for neglected tropical diseases is undergoing transformative shifts driven by scientific innovation, demographic pressures, and changing policy environments. Advances in diagnostic sensitivity and point-of-care testing are narrowing the gap between clinical detection and timely treatment, which in turn supports more precise use of targeted therapies alongside traditional mass drug administration campaigns. At the same time, drug development pipelines have diversified to include optimized anthelmintic regimens, combination therapies, and repurposed antibiotics that can be deployed in resource-limited settings with simplified administration protocols.

Simultaneously, broader systemic dynamics are reshaping program design. Urbanization and climate variability alter vector habitats and disease transmission patterns, prompting a recalibration of intervention zones and seasonality planning. Public procurement and supply chain resilience have become focal areas, with stakeholders investing in buffer stocks, decentralized warehousing, and digital inventory systems to reduce distribution lag. Finally, partnerships between public health authorities, non-governmental organizations, and private manufacturers are expanding, enabling collaborative financing models and pooled procurement mechanisms that enhance procurement efficiency and operational scalability.

Cumulative operational and procurement consequences stemming from United States tariff adjustments in 2025 that reshaped supply chains, sourcing strategies, and inventory planning across therapeutic categories

The introduction of tariffs and trade policy changes in 2025 materially influenced procurement dynamics and supply chain configurations for essential therapeutics used in neglected tropical disease programs. Increased tariff burdens on active pharmaceutical ingredients and formulation components amplified landed costs for some drug families, prompting procurement officers to reassess supplier portfolios and prioritize localized manufacturing where feasible. In response, supply chain managers accelerated efforts to qualify alternative suppliers, diversify logistics routes, and strengthen in-region contracting to buffer against future policy volatility.

Beyond direct cost effects, tariff-induced disruption had downstream implications for program timing and inventory planning. Organizations reliant on multi-stage international supply chains encountered longer lead times and heightened compliance requirements, which required earlier ordering windows and expanded coordination across customs, regulatory, and distribution partners. Moreover, tariff impacts intersected with existing regulatory complexity for active ingredients and finished products, intensifying the need for harmonized documentation and advance engagement with national authorities. As a consequence, program teams are increasingly embedding trade-policy scenario planning into annual procurement cycles and exploring contractual terms that allocate risk more explicitly between buyers and suppliers.

Segment-driven clinical and procurement imperatives that reconcile indication-specific needs, therapeutic classes, distribution pathways, and administration modes to optimize program delivery

A nuanced understanding of the market requires segmentation by indication, product class, delivery channel, end-user setting, route of administration, and treatment approach, each of which informs clinical decision-making and operational design. When examining disease indications such as dengue, lymphatic filariasis, onchocerciasis, schistosomiasis, and trachoma, program priorities differ markedly: vector control and rapid clinical management dominate dengue responses, whereas mass drug administration and morbidity management are central to lymphatic filariasis and onchocerciasis control efforts. Schistosomiasis interventions emphasize school- and community-based chemotherapy, and trachoma programs integrate antibiotic distribution with facial cleanliness and environmental measures.

Product-level segmentation similarly shapes procurement and clinical pathways. Anthelmintics, including widely used agents such as albendazole, ivermectin, and mebendazole, remain foundational for helminth control and require formulations suitable for mass administration. Antiarthropodals and insecticides underpin vector control strategies and are procured alongside pharmaceutical products to achieve integrated intervention packages. Antibiotics such as azithromycin and doxycycline have distinct roles in trachoma and certain bacterial sequelae, influencing dosing regimens and safety monitoring. Antiprotozoals, including meglumine, pentamidine, and suramin, cater to more specialized indications and often necessitate programmatic support for parenteral administration and adverse event surveillance.

Distribution channels also determine access dynamics. Government programs and NGO distribution platforms are primary conduits for large-scale campaigns, hospital pharmacies serve as referral hubs for complex cases, and retail pharmacies offer local access for routine care and follow-up. Correspondingly, end users vary from clinics and community health centers that deliver first-line preventive measures to hospitals and mobile camps that manage severe or rapidly evolving cases. Routes of administration-oral, parenteral, and topical-interact with service delivery capacity, with oral regimens generally preferred for scale, parenteral routes reserved for severe disease, and topical formulations supporting adjunctive care.

Finally, treatment approach differentiates program design: mass drug administration is effective for community-level burden reduction and elimination objectives, while targeted therapy allows clinicians to tailor regimens according to diagnostic confirmation and individual risk profiles. Taken together, these segmentation lenses provide a multidimensional perspective that facilitates targeted procurement, optimized clinical pathways, and tailored monitoring frameworks for diverse operational contexts.

Regional operational realities and epidemiological nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate adaptive treatment strategies and supply choices

Regional context significantly influences program priorities, regulatory navigation, and partnership models across the Americas, Europe Middle East & Africa, and Asia-Pacific, each presenting distinct epidemiological patterns and operational constraints. In the Americas, urbanization trends and heterogeneous health system capacities shape a dual focus on outbreak responsiveness for arboviral threats and sustained community-based control for helminth infections. Program implementers in this region often emphasize integration with primary healthcare platforms and leverage municipal health networks to extend outreach.

Across Europe, the Middle East & Africa, program responses contend with diverse regulatory environments and variable logistics infrastructure; integration of MDA campaigns with routine maternal and child health services has emerged as a pragmatic approach to broaden coverage in resource-limited settings. Humanitarian operations and cross-border coordination are particularly salient in parts of this region where displacement and conflict alter transmission dynamics and complicate supply continuity. In the Asia-Pacific, high population density in peri-urban zones, coupled with climatic influences on vector ecology, drives seasonally targeted interventions and school-based delivery models. Additionally, growing local manufacturing capacity and regional procurement consortia are enabling more resilient supply options, while digital health tools support community-level surveillance and adherence monitoring. These regional distinctions underline the importance of tailoring clinical protocols, distribution mechanisms, and partnership strategies to local realities.

How manufacturers, suppliers, and service providers are redefining competitive advantage through formulation innovation, localized production, and enhanced distribution capabilities

Industry participants and public-sector partners are adapting to a landscape where clinical efficacy, regulatory agility, and logistical competence determine competitive positioning. Pharmaceutical manufacturers focused on anthelmintics and antibiotics are investing in simplified dosing formulations and pediatric-friendly tablets to facilitate mass administration and improve adherence. At the same time, suppliers of antiarthropodals and insecticides are aligning formulations with integrated vector management programs, emphasizing safety profiles and environmental stewardship. Contract manufacturers and in-region production facilities are gaining strategic importance as stakeholders seek to reduce dependency on extended international supply chains and respond more nimbly to local demand fluctuations.

Service providers, including logistics firms and NGO implementers, are differentiating through expertise in cold-chain management for parenteral therapies, mobile outreach capabilities, and digital tracking systems that monitor campaign performance in real time. Regulatory consultancies and quality assurance partners play a critical role in accelerating product registration and ensuring compliance with national and regional standards. Collectively, these actors contribute to an ecosystem where collaboration, transparent contracting, and investment in capacity building are essential to sustain program momentum and expand access in challenging operational settings.

Practical strategic moves for leaders to strengthen program resilience, accelerate access, and align procurement and clinical strategies with local operational realities

Industry leaders and public health managers can advance impact by aligning strategic investments with operational realities and clinical priorities. First, prioritize formulation and delivery innovations that simplify administration and increase acceptability in community settings; this reduces reliance on intensive clinical infrastructure and supports higher coverage in mass drug administration contexts. Second, strengthen regional supplier networks and invest in local manufacturing partnerships to mitigate trade-policy risks and shorten lead times, while ensuring quality management systems are in place to maintain product integrity.

Third, integrate diagnostics and surveillance data into procurement and campaign planning so that targeted therapies complement mass administration where clinically appropriate; this will improve resource allocation and reduce unnecessary exposure to pharmacologic agents. Fourth, enhance supply chain transparency by adopting digital inventory and tracking solutions that enable proactive reallocation of stocks and more accurate anticipation of bottlenecks. Finally, deepen cross-sector collaborations that link public agencies, non-governmental implementers, clinical providers, and private manufacturers to coordinate financing, training, and community engagement. Taken together, these steps create a pragmatic roadmap for leaders to improve program resilience and accelerate progress against neglected tropical diseases.

A transparent methodology integrating clinical literature, implementation evaluations, regulatory analysis, and stakeholder interviews to ground operational conclusions in real-world evidence

The findings presented here synthesize multiple lines of evidence drawn from peer-reviewed clinical literature, program implementation reports, regulatory notices, and stakeholder interviews with procurement officers, clinicians, and supply chain specialists. Data synthesis prioritized recent peer-reviewed studies on treatment efficacy and safety, implementation evaluations of mass drug administration campaigns, and documented changes in trade and procurement policies. Qualitative inputs from field implementers and manufacturing partners informed assessments of operational feasibility and supply chain dynamics, providing real-world context to technical findings.

Analysis methods combined thematic synthesis for qualitative data with comparative review of regulatory and procurement practices across jurisdictions. Where applicable, triangulation between clinical evidence and operational experience guided conclusions about intervention suitability and distribution strategies. The methodology emphasized transparency in source selection, critical appraisal of evidence quality, and iterative validation with subject-matter experts to ensure that interpretations remain grounded in current practice and regulatory constraints.

Synthesis of strategic priorities that emphasize integration, localized capacity, and data-driven program design to sustain progress against neglected tropical diseases

In conclusion, the treatment landscape for neglected tropical diseases is at an inflection point where clinical advances, supply chain modernization, and adaptive policy responses must converge to sustain progress. Effective programs will blend mass drug administration with targeted clinical interventions, supported by stronger regional manufacturing capabilities, improved diagnostics, and digital tools that enhance supply chain responsiveness. Moreover, an emphasis on formulation innovation and community-centered delivery will be essential to expanding reach while preserving safety and acceptability.

Moving forward, stakeholders should prioritize cross-sector collaboration, investment in localized capacity, and integration of surveillance data into program design. By doing so, implementers and manufacturers can better anticipate disruptions, optimize resource use, and deliver treatments in ways that are both equitable and sustainable. These combined efforts will be critical to maintaining momentum against neglected tropical diseases in the years ahead.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neglected Tropical Disease Treatment Market, by Drug Type

• 8.1. Anthelmintics
  • 8.1.1. Albendazole
  • 8.1.2. Ivermectin
  • 8.1.3. Mebendazole
• 8.2. Antiarthropodals
• 8.3. Antibiotics
  • 8.3.1. Azithromycin
  • 8.3.2. Doxycycline
• 8.4. Antiprotozoals
  • 8.4.1. Meglumine
  • 8.4.2. Pentamidine
  • 8.4.3. Suramin
• 8.5. Insecticides

9. Neglected Tropical Disease Treatment Market, by Disease Indication

• 9.1. Dengue
• 9.2. Lymphatic Filariasis
• 9.3. Onchocerciasis
• 9.4. Schistosomiasis
• 9.5. Trachoma

10. Neglected Tropical Disease Treatment Market, by Route Of Administration

• 10.1. Oral
• 10.2. Parenteral
• 10.3. Topical

11. Neglected Tropical Disease Treatment Market, by Treatment Approach

• 11.1. Mass Drug Administration
• 11.2. Targeted Therapy

12. Neglected Tropical Disease Treatment Market, by End User

• 12.1. Clinics
• 12.2. Community Health Centers
• 12.3. Hospitals
• 12.4. Mobile Camps

13. Neglected Tropical Disease Treatment Market, by Distribution Channel

• 13.1. Government Programs
• 13.2. Hospital Pharmacy
• 13.3. NGO Distribution
• 13.4. Retail Pharmacy

14. Neglected Tropical Disease Treatment Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. Neglected Tropical Disease Treatment Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. Neglected Tropical Disease Treatment Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. United States Neglected Tropical Disease Treatment Market

18. China Neglected Tropical Disease Treatment Market

19. Competitive Landscape

• 19.1. Market Concentration Analysis, 2025
  • 19.1.1. Concentration Ratio (CR)
  • 19.1.2. Herfindahl Hirschman Index (HHI)
• 19.2. Recent Developments & Impact Analysis, 2025
• 19.3. Product Portfolio Analysis, 2025
• 19.4. Benchmarking Analysis, 2025
• 19.5. AbbVie Inc.
• 19.6. Amgen Inc.
• 19.7. Astellas Pharma Inc.
• 19.8. AstraZeneca plc
• 19.9. Bayer AG
• 19.10. Boehringer Ingelheim International GmbH
• 19.11. Bristol-Myers Squibb Company
• 19.12. Cipla Limited
• 19.13. Eisai Co., Ltd.
• 19.14. Eli Lilly and Company
• 19.15. Gilead Sciences, Inc.
• 19.16. GlaxoSmithKline plc
• 19.17. Glenmark Pharmaceuticals Ltd.
• 19.18. Hansa Biopharma AB
• 19.19. Johnson & Johnson Services, Inc.
• 19.20. Merck & Co., Inc.
• 19.21. Mylan N.V.
• 19.22. Novartis AG
• 19.23. Otsuka Pharmaceutical Co., Ltd.
• 19.24. Pfizer, Inc.
• 19.25. Regeneron Pharmaceuticals, Inc.
• 19.26. Sanofi S.A.
• 19.27. Serum Institute of India Pvt. Ltd.
• 19.28. Sumitomo Dainippon Pharma Co., Ltd.
• 19.29. Takeda Pharmaceutical Company Limited